Helicore Biopharma

Eight people. One molecule. A thesis the giants skipped.

Walk into the obesity drug market today and you will find a traffic jam. Eli Lilly and Novo Nordisk own the road. Their GLP-1 drugs print money and shed pounds. Into that crowd steps Helicore Biopharma - a company small enough to fit in a conference room, advancing a single antibody most of the industry has never put in a human.

Helicore does not want to be a louder version of what already works. It is built on a quieter idea: that the way the body loses weight matters as much as the number on the scale. While the field crowds around the GIP receptor, Helicore goes after the GIP ligand itself - the signal, not the switch.

GLP-1 drugs work. They also take the muscle with them.

Here is the inconvenient footnote to the weight-loss miracle: when patients drop 15 or 20 percent of their body weight on a GLP-1 drug, a meaningful chunk of that loss is lean mass - muscle, not just fat. For a 30-year-old that is a nuisance. For an older patient, it can be a problem worth its own clinic visit.

Then there is GIP, the field's favorite argument. Glucose-dependent insulinotropic polypeptide is an incretin hormone made almost entirely by K cells in the small intestine. For years, pharma has fought over whether you should agonize it or antagonize it. Tirzepatide agonizes the receptor. Amgen's antibody blocks it. The science has been, to put it politely, contested.

That is the tension this company exists inside. The obvious targets are taken. The mechanism is disputed. And the easy win - more weight loss - may come at the cost of the weight you actually want to keep.

Incubated in a lab in Basel, backed by people who have done this before.

Helicore did not start in a garage. It started inside Versant Ventures, the firm's fourth swing at obesity, engineered at Ridgeline - Versant's discovery engine in Switzerland. The bet was placed by people with scar tissue. Founding CEO Gerrit Klaerner had already co-founded Relypsa, the kidney-disease company Vifor Pharma bought for $1.5 billion in 2016. He has built and sold biotech before; he is not improvising.

The wager itself is precise: instead of blocking the GIP receptor, build an antibody that mops up the circulating GIP ligand before it ever reaches its target - including before it crosses into the brain. Neutralize the signal upstream, the thinking goes, and you act on both the gut and the central nervous system at once. You may even restore the body's sensitivity to leptin, the satiety hormone obesity tends to mute.

Better weight loss, less often.

Strip away the mechanism talk and the mission is plain: deliver obesity medicines that protect lean mass, work on both the gut and the brain, and ask less of the patient - a quarterly shot instead of a daily ritual. Helicore is wagering that the next chapter of obesity treatment is not about losing more, but losing better.

The competitive set is humbling - Lilly, Novo, Amgen, Structure, Metsera, a parade of well-funded incretin programs. Helicore's edge is not size. It is the single decision to target the GIP ligand directly, a lane that, for now, it has mostly to itself.

Back to the traffic jam.

Return to that crowded road. Lilly and Novo still own it. But the market they built is starting to ask harder questions - about muscle, about durability, about patients who would rather not inject themselves every week. Those questions are exactly the ones Helicore was built to answer.

Eight people cannot out-shout two pharma titans. They do not need to. They need one antibody to do something the giants' drugs do not, and a safety read clean enough to keep going. As of 2026, they have the second and are chasing the first. The quiet company that walked the other way is still walking - and the road it picked is, for the moment, empty.